Spero Therapeutics (SPRO) Total Liabilities (2016 - 2026)

Spero Therapeutics (SPRO) has reported Total Liabilities for 11 consecutive years, with $8.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 70.77% year-over-year to $8.6 million; the trailing twelve-month figure through Jun 2026 stood at $8.6 million (down 70.77% YoY), and the FY2025 full-year result was $9.9 million, down 84.64% from the prior year.
• Total Liabilities climbed to $8.6 million in Q2 2026 per SPRO's latest filing, from $6.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $83.4 million in Q1 2022 and bottomed at $6.1 million in Q1 2026.
• Historically, Total Liabilities has averaged $45.2 million across 5 years, with a median of $45.9 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 238.93% in 2022, then plunged 86.13% in 2026.
• Over 5 years, Total Liabilities stood at $48.9 million in 2022, then soared by 54.49% to $75.5 million in 2023, then fell by 14.67% to $64.4 million in 2024, then slumped by 84.64% to $9.9 million in 2025, then declined by 13.5% to $8.6 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $8.6 million, $6.1 million, and $9.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.